Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

Journal of Medical Economics

Volumn 16, Issue 7, 2013, Pages 917-925

  Kane, John M ^a   Sanchez, Raymond ^b   Zhao, Joan ^b   Duca, Anna R ^b   Johnson, Brian R ^b   McQuade, Robert D ^b   Eramo, Anna ^c   Baker, Ross A ^b   Peters Strickland, Timothy ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

Aripiprazole once monthly; Hospitalisations; Mirror image study; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; COMMUNITY; CONTROLLED RELEASE FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; INSOMNIA; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MULTICENTER STUDY; NEUROLOGIC DISEASE; NORTH AMERICA; PARANOIA; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STUDY DESIGN; SUICIDE ATTEMPT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; COMMUNITY MENTAL HEALTH SERVICES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NORTH AMERICA; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; STANDARD OF CARE;

EID: 84879744844     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.804411     Document Type: Article

References (31)

1. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011;475:27-30
2. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
3. World Health Organization. WHO. http://www.who.int/mental-health/ management/schizophrenia/en. Accessed 2012
4. Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral anti-psychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
5. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
6. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
7. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehos-pitalization among California Medicaid patients with schizophrenia. Psychiatric Serv 2004;55:886-91
8. Weiden P, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
9. Marcus S, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-80
10. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
11. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res 2011;127:83-92
12. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
13. De Berardis D, Marini S, Carano A, et al. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Current Clin Pharmacol 2013:[Epub ahead of print]
14. FDA. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails
15. Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
16. Otsuka America Pharmaceuticals Inc. Abilify Maintena Prescribing Information. 2013. http://www.otsuka-us.com/Products/Documents/Abilify. M.PI.pdf
17. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77
18. Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16: 522-8
19. Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of lai formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Rers 2013. [Epub ahead of print]
20. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23(1 Suppl):35-47
21. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75-89
22. Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risper-idone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
23. Haddad P, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry 2009;52: S20-8
24. Asseburg C, Willis M, Lothgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in finland before and after initiation of risperidone long-acting injection. Schizophr Res Treat 2012;2012:791468. doi: 10.1155/2012/791468
25. Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig 2010;30: 777-87
26. Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract 2010;14:53-62
27. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12: 317-24
28. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14
29. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull [Epub ahead of print]
30. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole. 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2-6 December 2012; Hollywood, FL
31. Essock S, Covell N, Davis S, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-5